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EDITORIAL
Can angiotensin II be used for renoprotection?
The renin-angiotensin-aldosterone-system (RAAS) has confirmed by many and led to a whole new avenue of
been a target for research since 1898 when Tigerstedt research, claiming that ACE inhibition was not only the
and Bergmann injected a crude extract of the kidney result of RAAS intervention, but in fact related to inter-
(called renin) into a rabbit resulting in a rise in blood vention in the bradykinin system. The first studies with
pressure [1]. We have since learned that this system plays an even more specific Ang II intervention strategy, that
an important and sometimes even crucial (physiological) is, blocking the angiotensin (AT1) receptor, were actually
role in regulating different (ad)renal functions, such as expected to therefore have a different effect on outcome
blood pressure and electrolyte and water hemostasis. In compared to ACE inhibitors. ACE inhibitors were sup-
addition, the RAAS is found to be a key player in the posed to have something extra. However, to our surprise,
pathology of accelerated loss of organ or tissue function, the comparative data of ACE inhibitors and Ang II re-
including the kidney and other cardiovascular systems. ceptor antagonist effects gave quite similar results [3].
Several receptor-mediated actions of angiotensin II (Ang This moved researchers toward a new hypothesis to ex-
II) are involved in these (patho)physiological effects, plain the discrepancy between Ang II plasma levels and
including vascular contractility, cell transport, and cell ACE inhibitor effects. Currently, the most popular ex-
growth. planation is that it is not circulating Ang II that we should
The most compelling evidence for these (patho)physi- be looking for, but local or tissue angiotensin levels that
ological RAAS functions stems from the studies in which dictate the physiology, as well as the pathophysiology.
the system was stimulated or inhibited. Particularly, the Consequently, therapeutic effects have also to be studied
latter was of paramount importance, since it offered po- in the light of local tissue inhibition. In this issue of
tential therapeutic modalities to be discovered. Indeed, Kidney International, Wenzel et al present some very
from snake venom to angiotensin-converting enzyme interesting data that again challenge us to rethink the
(ACE) inhibitors and from molecular design to Ang pathophysiological role of Ang II [4]. These authors actu-
II receptor antagonist has been a major cardiovascular ally found that infusion of exogenous Ang II may protect
research story, as well as therapeutic success story, for the kidney against loss of function subsequent to an
patient, physician, and pharmaceutical industry. Al- “attack.” The authors substantiated this finding with sev-
though it is one of the most intensively studied hormonal eral appropriate control studies, including the study in
systems, many questions still remain unanswered about which they prevented this renal protective effect of Ang
its exact role, particularly the mechanism underlying the II by Ang II receptor blockade. This finding goes against
above (patho)physiological effects, and the uncertainty the grain of all previous data. In fact, there is overwhelm-
about the mechanism of action of drugs like ACE inhibi- ing evidence that similar exogenous infusions of Ang II in
tors and Ang II receptor antagonists. One intriguing ex- different animal models, in fact, leads to (renal) damage,
ample comes to my mind. ACE inhibitors were the first instead of protection against it [5–11]. In addition, there
practical drugs specifically inhibiting the RAAS by pre- is just too much evidence for a renal protective effect of
venting the formation of Ang II out of angiotensin I. ACE inhibitors, as well as Ang II receptor antagonists
These drugs indeed very effectively reduced plasma (both experimental and clinical). How then can we ex-
ACE activity, while at the same time the expected effects plain this remarkable finding? Wenzel et al have several
on Ang II-regulated parameters were reduced. Most im- intriguing explanations, most of them dealing with the
portant, one found a reduction in blood pressure, in- notion that Ang II may play an indirect role in organ
creased electrolyte excretion, and also reduction in pro- protection by intervening in the immunologic defense
gressive loss of organ function. Thus ACE inhibitors system. Although this appears to be logical, looking at
were in the beginning considered to be very specific their data, it still does not explain why no other study
drugs for reducing activity of the RAAS. However, sur- to date has found a protective effect of Ang II. It may,
prisingly, the effects were not related to a true reduction therefore, be more important to look at the data the
of Ang II plasma levels [2]. These “shocking” data were authors did not gather or rather could not gather. Again,
as stated above, we have to rely for such a new concept
on exogenous infusion studies with Ang II. From suchKey words: renin-angiotensin-aldosterone system, angiotensin-convert-
ing enzyme inhibitors, exogenous infusion studies. data we conclude like the authors that “activation of the
RAAS may have protective effects in certain pathophysi- 2002 by the International Society of Nephrology
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ological conditions.” However, to reiterate my earlier different way of thinking about the RAAS than is cur-
rently the case, I have my doubts. However, the datastatement in the first paragraph, we must make distinc-
will contribute to further develop a new avenue of think-tions between circulating RAAS and local (tissue) RAAS.
ing for new preventive protection measures to battle pro-Exogenous infusion of Ang II can, in my opinion, only
gressive renal function loss.be considered to increase the systemic (circulating) levels
of Ang II and not the local renal levels. Much of that is
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Ang II found in the renal vein is de novo synthesized in
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